Skip to main content

Table 1 Demographic and baseline characteristics of 138 patients with metastatic breast cancer

From: Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer

Characteristic

HT group (n = 59)

MCT group (n = 79)

P value

Age (years)a

  

0.009 (t test)

Median

49

50

 

 Range

37–76

34–66

 

KPS score

  

0.349

 90–100

46 (78.0)

56 (70.9)

 

 70–80

13 (22.0)

23 (29.1)

 

Menopausal status

  

0.520

 Premenopausal

20 (33.9)

31 (39.2)

 

 Postmenopausal

39 (66.1)

48 (60.8)

 

HR status

   

 ER-positive

55 (93.2)

73 (92.4)

0.855

 PgR-positive

51 (86.4)

65 (82.2)

0.509

Adjuvant HT

  

0.246

 Yes

50 (84.7)

72 (91.1)

 

 No

9 (15.3)

7 (8.9)

 

DFS (years)

  

0.446

 <2

16 (27.1)

17 (21.5)

 

 ≥2

43 (72.9)

62 (78.5)

 

 Mediana (months)

44

42

0.178 (t test)

No. of metastases

  

0.006

 <2

30 (50.9)

22 (27.9)

 

 ≥2

29 (49.1)

57 (72.1)

 

Metastatic sites

  

0.168

 Viscera

32 (54.2)

52 (65.8)

 

 Non-viscera

27 (45.8)

27 (34.2)

 

Prior adjuvant CT

   

 Anthracycline

54 (91.5)

70 (88.6)

0.749

 Taxanes

32 (54.2)

53 (67.1)

0.170

Response to FCCT

  

0.009

 CR + PR

28 (47.4)

55 (69.6)

 

 SD

31 (52.3)

24 (30.4)

 
  1. HT hormonal therapy, MCT maintenance capecitabine monotherapy, KPS Karnofsky performance status, HR hormone receptor, ER estrogen receptor, PgR progesterone receptor, DFS disease-free survival, CT chemotherapy, FCCT first-line capecitabine-based combination chemotherapy, CR complete response, PR partial response, SD stable disease
  2. aExcept for these values, others are presented as the numbers of patients followed by the percentages in the parentheses